Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sigma-Aldrich has acquired a minority stake in life science company, Genospectra, and has also gained access to various technologies developed by the company. The agreement strengthens Sigma-Aldrich's position in the areas of RNA interference, gene expression and cell based assays.
Subscribe to our email newsletter
Under the agreed upon terms Sigma-Aldrich gained access to the QuantiGene gene expression profiling assay and Genospectra’s technologies for inducible siRNA, a unique nano-particle system for delivery of siRNA and other biomolecules to cells.
The companies will participate in a joint program to develop new technology and products in the area of cell-based assays.
“Sigma-Aldrich’s leadership and capabilities in technology commercialization and product development, combined with Genospectra’s cutting edge platforms in the area of systems biology, provides significant potential for success,” said Dr David Smoller, vice president of R&D for Sigma-Aldrich’s research biotech business unit.